During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Hepatologist highlights that zinc supplements do not prevent illness or improve health outcomes. He emphasises the lack of ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...

Nepal, June 27 -- based foods is often seen as another wellness trend, something to try for a week and forget. But when ...